Systematic (IUPAC) name | |
---|---|
N,N-diethyl-4-((8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl)benzamide | |
Clinical data | |
Pregnancy cat. | ? |
Legal status | Legal |
Identifiers | |
ATC code | ? |
PubChem | CID 10205965 |
Chemical data | |
Formula | C33H38N2O |
Mol. mass | 478.667 g/mol |
SMILES | eMolecules & PubChem |
(verify) |
(what is this?)
RWJ-394674 is a drug which is used in scientific research. It is a potent, orally active analgesic drug, which produces little respiratory depression. RWJ-394674 itself is a potent and selective agonist for δ-opioid receptors, with a Ki of 0.24 nM at δ and 72 nM at μ. However once inside the body, RWJ-394674 is dealkylated to its monodesethyl metabolite RWJ-413216 which is a potent agonist at the μ-opioid receptor and has less affinity for δ (Ki 0.26 nM at μ, 46.7 nM at δ). The effect of RWJ-394674 when administered in vivo thus produces potent agonist effects at both μ and δ receptors through the combined actions of the parent drug and its active metabolite, with the δ-agonist effects counteracting the respiratory depression from the μ-opioid effects, and the only prominent side effect being sedation.[1]